Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet. In first-line therapy, patients receiving sorafenib had increased overall survival and progression free survival. Therefore several antiangiogenic agents have entered clinical studies on HCC, many with negative results. This review discusses the current drug development for patients with HCC and role of TACE plus sorafenib.
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review / Casadei Gardini, Andrea*; Santini, Daniele; Aprile, Giuseppe; Silvestris, Nicola; Felli, Emanuele; Foschi, Francesco Giuseppe; Ercolani, Giorgio; Marisi, Giorgia; Valgiusti, Martina; Passardi, Alessandro; Puzzoni, Marco; Silletta, Marianna; Brunetti, Oronzo; Cardellino, Giovanni Gerardo; Frassineti, Giovanni Luca; Scartozzi, Mario. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 8:39(2017), pp. 66699-66708. [10.18632/oncotarget.19449]
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review
Ercolani, GiorgioInvestigation
;
2017
Abstract
Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet. In first-line therapy, patients receiving sorafenib had increased overall survival and progression free survival. Therefore several antiangiogenic agents have entered clinical studies on HCC, many with negative results. This review discusses the current drug development for patients with HCC and role of TACE plus sorafenib.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
